Sirona Biochem Corp. (TSX-V:SBM, OTC:SRBCF) today announced it is setting up a new lab dedicated to commercializing its anti-aging skin serum.
Sirona has two main products – one a diabetes drug that it licences, and an anti-aging skin serum called GlycoProteMim.
Sirona says it will establish Sirona Laboratories as a wholly owned subsidiary for the commercialization of GlycoProteMim, which was recently trademarked.
“We’ve opted for a course of action that is primed to transform, not just Sirona Biochem’s prospects, but that of the entire anti-aging market,” Sirona CEO Howard Verrico said in a press release.
Sirona Biochem is inviting “major industry players” to partner with Sirona in the new lab.
“The company’s clinically proven science, combined with the unmet commercial opportunity, positions Sirona Laboratories at the forefront of skincare innovation,” said Geraldine Deliencourt-Godefroy, Sirona’s chief science officer.
“We are eager to leverage our expertise and take GlycoProteMim to new heights, while also setting a new benchmark for anti-aging treatments.”
